In some cases, they may suggest decreasing your dosage of Ozempic or other diabetes medications you take
Rybelsus (oral semaglutide) the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke Novo Nordisk today announced that the European Medicines Agencys Committee for Medicinal Products for Human Use has approved an update to the Rybelsus (oral semaglutide) label to reflect the cardiovascular benefits seen in the SOUL trial.
While not officially approved for treating BED, it may assist with controlling binge eating episodes due to its effect on appetite regulation and satiety
Santos Febles E, Ontivero Ortega M, Valds Sosa M, Sahli H
Plan Ahead: Maximizing Your HSA or FSA for GLP-1 If you carry an HSA and are considering GLP-1 therapy, plan to enroll before your annual HSA contribution limit is reached
Signs Your Thyroid Function May Be Shifting on GLP-1 Therapy When thyroid hormone absorption drops, symptoms can develop slowly and feel vague
